This press release contains no new clinical data or regulatory milestones. The stock is unlikely to react to a presentation announcement alone. Traders should focus on the RENEW Phase 2 data readout timeline for a material catalyst.
Price Chart
Executive Summary
Rein Therapeutics announced a late-breaking poster presentation on LTI-03 at the ERS 2026 Congress, with data already published in Nature Communications. The presentation covers a Phase 1 dose escalation study in IPF, but no new efficacy or safety results are disclosed in this release. This is a routine scientific communication with no immediate stock-moving catalyst.
Key Facts
- Late-breaking poster on LTI-03 to be presented at ERS 2026 Congress on September 8, 2026
- Data published in Nature Communications — not new results
- LTI-03 is a first-in-class inhaled peptide for IPF with Orphan Drug and Fast Track designations
- RENEW Phase 2 trial is ongoing, targeting ~120 patients with FVC as primary efficacy endpoint
Financial Impact
No financial figures disclosed in this release
Risk Factors
- Clinical trial risk — IPF is a difficult indication with high failure rates
- Competition from approved therapies (pirfenidone, nintedanib) and other pipeline candidates
- Early-stage company with no approved products and reliance on LTI-03 as lead candidate
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3356530 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | Press Release | $0.8891 | awaiting T+60 | — | $0.5830 (−34.43%) |
Aug 14, 2026 10w ago | Press Release | $0.8060 | awaiting T+60 | — | $0.5830 (−27.67%) |
Jul 21, 2026 14w ago | Press Release | $0.8948 $0.7546 | ▼ −15.67% | ▼ −19.64% | $0.5830 (−34.85%) |
Jun 8, 2026 20w ago | DEFA14A | $0.9487 $0.7527 | ▼ −20.66% | ▼ −23.71% | $0.5830 (−38.55%) |
May 4, 2026 25w ago | 8-K | $1.02 $0.7680 | ▲ +24.71% | ▲ +27.45% | $0.5830 (+42.84%) |
May 4, 2026 25w ago | 424B5 | $1.02 $0.7580 | ▲ +25.69% | ▲ +27.54% | $0.5830 (+42.84%) |
May 1, 2026 25w ago | Press Release | $1.03 $0.7818 | ▲ +24.10% | ▲ +27.17% | $0.5830 (+43.40%) |
Apr 29, 2026 25w ago | Press Release | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5830 (−54.27%) |
Apr 28, 2026 25w ago | S-1 | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.5830 (−54.27%) |
Apr 27, 2026 26w ago | 10-K/A | $1.49 $0.8400 | ▼ −43.62% | ▼ −48.40% | $0.5830 (−60.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers